Intech Business Summary

Intech Biopharm Corporation (6461.TWO) is a specialized pharmaceutical firm focused on the development and high-volume manufacturing of respiratory therapies, primarily utilizing pressurized Metered Dose Inhaler (pMDI) and Dry Powder Inhaler (DPI) technologies. The company generates revenue through a multi-pronged model involving the sale of proprietary respiratory products—such as Duasma and Synvent HFA MDIs—milestone-based international licensing agreements, and specialized manufacturing services for high-barrier generics and 505(b)(2) combination drugs. In fiscal year 2025, Intech achieved a substantial revenue increase to TWD 107.53 million, leveraging its iMET (Inhalation Manufacturing & Execution Technology) platform and an FDA/EMA-standard facility with an annual capacity of 15 million MDI units. Globally, Intech competes with respiratory leaders such as Teva Pharmaceutical Industries, Lupin, and Glenmark Pharmaceuticals, positioning itself as a technically superior regional specialist compared to local peers like Innopharmax and SynCore Biotechnology. The executive leadership is headed by CEO Manish Chawla, who assumed the role in January 2025 following a distinguished career in multinational R&D at Lotus Pharmaceutical, Zydus Cadila, and Dr. Reddy’s Laboratories. The company is chaired by Lin Chih-Hui, who maintains the strategic alignment with the founding Synmosa Group, Intech’s primary institutional investor and corporate partner. The governance structure was further strengthened in January 2026 with the appointment of Wang Tzyy-Po, Senior Vice President at Harbinger Venture Management, as a corporate representative director. This leadership team integrates decades of specialized inhalation R&D with robust venture capital oversight, focusing on the global commercialization of its Phase 3 pipeline candidates and expanding its footprint in the U.S. and Chinese respiratory markets.